Bovie Medical Corporation (the “Company”) (NYSE-AMEX Symbol: BVX), a
manufacturer and marketer of electrosurgical products, today announced
the Company has received 510(k) clearance from the Food and Drug
Administration (FDA) to market its J-Plasma ICON GS electrosurgical
generator and handpiece.
The technology utilizes a gas ionization process producing a stable thin
focused beam of ionized helium gas that can be controlled in a wide
range of temperatures and intensities, providing the surgeon greater
precision, minimal invasiveness and an absence of conductive currents
during surgery. Independent control of the beam power (heating) and
helium flow rate (cooling) produces a highly localized effect with
minimal collateral damage to the surrounding healthy tissue.
Management believes the J-Plasma technology has a wide variety of
medical applications including dermatology, gynecology, hepatobiliary
(liver), thoracic and general surgery. The Company is consulting with
both domestic and international physicians and scientists experienced in
the field of plasma medicine to accelerate the commercialization of the
technology in the U.S. and abroad. Worldwide revenues for the targeted
surgical procedures are estimated to exceed $2 billion.
Mr. David Uffer, vice president of advanced technologies and director of
plasma sales and marketing will lead the Company’s efforts in developing
the technology’s applications and commercialization.
Andrew Makrides, president of Bovie Medical stated, “Management remains
very encouraged regarding the potential of the J-Plasma technology. The
FDA clearance to market J-Plasma is a milestone in our continued
evolution into a high-tech medical device company.”
For further information about the Company’s current and new products,
please refer to the Investor Relations section of Bovie’s website www.boviemedical.com.
This document may contain some forward looking statements, particularly
regarding operational prospects in 2009 and beyond, which involve a
number of risks and uncertainties that could cause actual results to
differ materially. These risks are listed from time to time in the
Company’s SEC filings.
Investor:
Buttonwood Advisory Group, Inc.
John Aneralla,
1-800-940-9087
